Noul Co. Ltd.’s Micro-Intelligent Laboratory, an artificial intelligence-powered diagnostic system, demonstrated superiority over microscopic diagnosis for malaria in a study presented at the 2024 ...

Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick ...

Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of RLS Radiopharmacies for ...

Onward Medical NV successfully implanted its Arc-BCI system, which restores direct communication from the brain to the spinal ...

Researchers from UCLA’s Department of Cardiac Surgery filed for protection of a smart multistage peripherally inserted ...

Nicox SA has entered into an exclusive research and license option agreement with Glaukos Corp. for NCX-1728, Nicox’s novel ...

Investigators from Abzyme Therapeutics LLC have hypothesized that inhibiting this pathway in the CNS may prevent tissue ...

The U.S. FDA wrapped up the pilot version of the Accreditation Scheme for Conformity Assessment (ASCA) and reported the ...

Ascletis Pharma Inc. is entering the obesity space, announcing it has begun two phase I trials for ASC-30, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that can be dosed once ...

Vicebio Ltd. is funded to take two of its molecular clamp respiratory infection vaccines through phase II development, after raising $100 million in a series B.

An innovation that has kickstarted a revolution in the study and practice of health care is getting even more attention.

A little more than a year after the U.S. FDA refused to review the NDA for Biohaven Ltd.’s ultra rare disease treatment, new and positive phase III data have changed the treatment’s momentum. The ...